Calico Labs

Research and develop treatments for aging

South San Francisco, California, United States

About Calico Labs

Calico Labs focuses on researching the biology of aging and creating treatments for age-related diseases. The company conducts scientific research to understand how aging works and the diseases that come with it. By collaborating with academic institutions and other biopharmaceutical companies, Calico Labs combines advanced technologies with a culture of curiosity to drive innovation in this field. This partnership approach helps speed up research and increases the chances of making important discoveries. Calico Labs earns revenue through these collaborations, which often include joint research projects and shared developments of new therapies. The goal of Calico Labs is to significantly advance the understanding of aging and develop effective treatments for age-related conditions.

South San Francisco, CaliforniaHeadquarters
2013Year Founded
$2MTotal Funding
SEEDCompany Stage
Biotechnology, HealthcareIndustries
201-500Employees

Benefits

Performance Bonus
Professional Development Budget

Risks

Over-reliance on AbbVie partnership could pose risks if strategic misalignments occur.
Focus on rare diseases like VWM may limit market size and revenue potential.
Intensifying competition in anti-aging research could dilute Calico's market influence.

Differentiation

Calico Labs focuses on aging and age-related diseases, a niche in biopharmaceuticals.
The company leverages strategic partnerships, enhancing research and development capabilities.
Calico's collaboration with Broad Institute targets age-related neurodegeneration, extending until 2029.

Upsides

Calico's drug fosigotifator is in the FDA's START Pilot Program, accelerating development.
The company benefits from Google's $1.5B investment, boosting financial stability.
Calico's AI-driven drug discovery approach aligns with industry trends, enhancing innovation.